Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR Li-Kuei ChenChien-Hung ShihKuen-Bao Chen Research 09 August 2022 Pages: 1165 - 1172
Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine Haiqin PingWenjun YuHengning Ke Research 13 August 2022 Pages: 1173 - 1184
Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer Imene Ben ToumiaMarco PonassiCamillo Rosano Research 17 August 2022 Pages: 1185 - 1193
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations Jiajia YuanJunzhe SongYuan Zhou Research 31 August 2022 Pages: 1194 - 1205
Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics Zhitao NiShaolin XuXiuhua Zhang Research 05 September 2022 Pages: 1206 - 1215
Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα Zhiwei ChenXing XiaLongfa Kou Research 07 September 2022 Pages: 1216 - 1230
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia Yanfeng LiuYan JiaMei Zhang Research 26 October 2022 Pages: 1231 - 1243
TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells’ killing Xuejia FengGui YangQingxia Wu Research 28 October 2022 Pages: 1244 - 1253
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer Hayato YokotaKazuhiro SatoMasatomo Miura Research 23 September 2022 Pages: 1254 - 1262
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors Emiliano CalvoCristiana SessaAlexander Drilon Research Open access 10 August 2022 Pages: 1263 - 1273
Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects Linlin HuMingmin CaiHuiping Wang Research 10 September 2022 Pages: 1274 - 1281
Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study Peng ShenBo QiaoShuyan Wang Research 16 August 2022 Pages: 1282 - 1289
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab Nobuharu TamakiToshifumi TadaNamiki Izumi Research 24 September 2022 Pages: 1290 - 1297
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer Toshiyuki SumiYuta KoshshinoHirofumi Chiba Research 13 October 2022 Pages: 1298 - 1305
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161 Lakshmi RajdevJu-Whei LeePeter J. O’Dwyer Research 20 October 2022 Pages: 1306 - 1314
Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer Toshiyuki SumiMotoki SekikawaHirofumi Chiba Research 21 October 2022 Pages: 1315 - 1321
BMP2 as a promising anticancer approach: functions and molecular mechanisms Tong-tong LiYong-wei LaiPeng-xia Zhang Review 30 August 2022 Pages: 1322 - 1332
CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma Bo XuShaoqian LiJiecan Zhou Review 08 September 2022 Pages: 1333 - 1341
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy Shinsuke OgusuRyo AriyasuMakoto Nishio SHORT REPORT 24 September 2022 Pages: 1342 - 1349
A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report Chunguang WangShu ChenPeiran Xu Case Report 06 June 2022 Pages: 1350 - 1353
Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations Shinichiro OkauchiHiroaki Satoh Correspondence 24 September 2022 Pages: 1354 - 1355
Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine Haiqin PingWenjun YuHengning Ke Author Correction 27 August 2022 Pages: 1356 - 1356
Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report Chunguang WangShu ChenPeiran Xu Publisher Correction 16 August 2022 Pages: 1357 - 1357